BILOPAQUE
LOE ApproachingNDAORALCAPSULE
Approved
Oct 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BILOPAQUE is an oral diagnostic capsule approved in 1969 by GE HealthCare for radiographic visualization of the biliary system. The drug is a contrast agent administered via oral route to enable imaging of bile ducts and gallbladder function. Mechanism of action involves radiopaque properties that enhance contrast in diagnostic imaging procedures.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating a contracting team focused on margin preservation rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Minimal linked job openings (0) reflect the product's mature, declining lifecycle stage. Roles in this product are primarily focused on protecting remaining market share and managing transition rather than growth or innovation.
Brand ManagerProduct Manager
Worked on BILOPAQUE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.